Subcutaneous immunoglobulin — the future of CIDP treatment?

被引：0

作者：

Benjamin R. Wakerley

Nobuhiro Yuki

机构：

[1] Gloucestershire Royal Hospital,Benjamin R. Wakerley is at the Department of Neurology, UK; and at the Nuffield Department of Clinical Neurosciences

[2] Great Western Road,and at the Nuffield Department of Clinical Neurosciences

[3] Gloucester GL1 3NN,Nobuhiro Yuki is at the Department of Medicine

[4] University of Oxford,undefined

[5] John Radcliffe Hospital,undefined

[6] Headley Way,undefined

[7] OX3 9DU,undefined

[8] Oxford,undefined

[9] UK.,undefined

[10] University of Oxford,undefined

[11] John Radcliffe Hospital,undefined

[12] Headley Way,undefined

[13] OX3 9DU,undefined

[14] Oxford,undefined

[15] UK.,undefined

[16] Eda Memorial Hospital,undefined

[17] Azamino-minami 1-1-1,undefined

[18] Aoba-ku,undefined

[19] Yokohama,undefined

[20] Kanagawa,undefined

[21] 225-0012,undefined

[22] Japan.,undefined

来源：

Nature Reviews Neurology | 2018年 / 14卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). This finding represents an important step in the management of patients with immunoglobulin-responsive CIDP, with considerable implications for the cost of treatment and, most importantly, for these patients' quality of life.

引用

页码：130 / 131

页数：1

共 50 条

[31] SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP AND MMN: FRENCH EXPERIENCE ON 28 PATIENTS
Cauquil, C.
Viala, K.
Le Masson, G.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 166 - 166
[32] Analysis of relapse by I-RODS status in the PATH study of subcutaneous immunoglobulin in CIDP
Merkies, Ingemar
van Schaik, Ivo
Bril, Vera
van Geloven, Nan
Hartung, Hans-Peter
Lewis, Richard
Sobue, Gen
Lawo, John-Philip
Mielke, Orell
Durn, Billie
Cornblath, David
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 309 - 309
[33] A COMPARISON OF THE EFFECT OF SUBCUTANEOUS VS INTRAVENOUS IMMUNOGLOBULIN THERAPY ON QUALITY OF LIFE IN PATIENTS WITH CIDP
Vu, Tuan
Natalie, Tucker
Alsina, Raul
Harvey, Brittany
Farias, Jerrica
Gooch, Clifton
MUSCLE & NERVE, 2018, 58 : S58 - S58
[34] Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
Hadden, Robert D. M.
Marreno, Fabrizio
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 14 - 19
[35] NERVE LESIONS CAN BE DETECTED BY DIFFUSION TENSOR IMAGING IN PATIENTS WITH CIDP TREATED WITH SUBCUTANEOUS IMMUNOGLOBULIN
Markvardsen, L.
Vaeggemose, M.
Ringgaard, S.
Andersen, H.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 192 - 192
[36] Improvement of haemoglobin level following switch from intravenous to subcutaneous administration of immunoglobulin in CIDP and MMN
Christiansen, I.
Markvardsen, L. H.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 340 - 340
[37] Immunogenicity in a Phase 3 facilitated subcutaneous immunoglobulin study in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Hasan, Shabbir
Wisseh, Steve
Ay, Hakan
Duff, Kim
Nagy, Andras
Chavan, Shailesh
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 538 - 538
[38] Quality of life, disability and weekly dosage indicate remission in CIDP patients treated with subcutaneous immunoglobulin
Markvardsen, Lars
Sindrup, Soren
Jeppesen, Tina
Andersen, Henning
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 321 - 322
[39] CIDP - intravenous immunoglobulin or corticosteroids?
Neacsu, M. G. Giurea
Ioan, B.
Buraga, M.
Baetu, C.
Cioriceanu, I-H
Ghitoiu, A. M.
Enachi, A. M.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 737 - 737
[40] SUBCUTANEOUS IMMUNOGLOBULIN HOME TREATMENT IN HYPOGAMMAGLOBULINEMIA
LEAHY, MF
LANCET, 1986, 2 (8497): : 48 - 48

← 1 2 3 4 5 →